Amgen entered into an agreement to acquire Tularik, substantially increasing its product portfolio in the areas of cancer, inflammatory disease, type 2 diabetes and obesity, in addition to gene expression platform focused on selectively blocking inflammatory cell signaling pathways. The deal could be worth up to US$1.3 B to Tularik.